Taylor Duncan

Taylor Duncan is a Manager in the Life Sciences Practice. She specializes in integrating research and qualitative analyses into a format digestible for quantitative analyses. Her work focuses on healthcare engagements in the pharmaceutical industry regarding public and private health insurance, drug pricing, and allegations of false claims. Ms. Duncan has significant experience performing document review, building databases, assessing claim reviews, and compiling data in a systematic, thematic, and consistent manner. She also has experience in antitrust litigation, supporting experts and counsel in matters involving price-fixing, monopolization, conspiracy, class certification, and product hopping. Her other casework has involved the determination of royalty rates, insurance coverage disputes, and intellectual property rights.

BA, Psychology and Sociology, University of Virginia

• Supported the testimony of Dr. Nicholas Hill on behalf of the Department of Justice in its successful litigation to block the merger of Penguin Random House and Simon & Schuster.
• Supported the experts in several confidential matters on behalf of multiple insurers concerning insurance policies taken out by opioid distributors and dispensers.
• In In re Teva Securities Litigation, supported the expert’s work on antitrust issues associated with alleged misrepresentations regarding the sources of Teva’s profits and the competitiveness of markets for generic drugs.
• In In re EpiPen ERISA Litigation, supported academic affiliate’s expert analyses of economic issues related to class certification on behalf of a joint defense group of leading pharmacy benefit managers facing allegations that they breached purported fiduciary obligations associated with EpiPen® rebates.
• Provided support on a confidential matter on behalf of numerous health insurers concerning coverage for an infectious disease.
• In Sandoz Inc. v. United Therapeutics Corporation, supported the expert regarding issues of market definition, market power, competitive effects, and irreparable harm on behalf of United Therapeutics and Smiths Medical..
• In United States and State of New York ex rel. Lacey v. Visiting Nurse Service of New York (VNSNY),  supported expert’s analyses on behalf of VNSNY.
• Supported the testifying expert on a confidential matter on behalf of pharmaceutical manufacturers concerning allegations of price-fixing
• In State of Wisconsin et al. v. Indivior Inc. f/k/a Reckitt Benckiser Pharmaceuticals Inc. et al., supported testifying experts on behalf of the plaintiff states and a class of direct purchasers regarding economic issues associated with the product hop behavior, including disgorgement, and the relevant market and whether Reckitt’s alleged behavior harmed competition.
• In Medical Mutual of Ohio v. AbbVie Inc., supported testifying expert regarding economic issues associated with class certification and merits on behalf of a joint defense group of leading testosterone replacement therapy manufacturers in connection with alleged RICO and antitrust violations.
• In Elorac v. Sanofi-Aventis Canada, supported the expert in assessing damages in a breach of contract federal district court action on behalf of the plaintiff.
• In United States ex rel. Donald R. Galmines v. Novartis Pharmaceuticals Corp. supported the testifying expert on causation and damages on behalf of Novartis in connection with alleged FCA violations.